Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Furie, Richard; A. Khamashta, Munther; T. Merrill, Joan; P. Werth, Victoria; Kalunian, Kenneth; Z. Brohawn, Philip; G. Illei, Gabor; Drappa, Jörn; Wang, Liangwei; Yoo, Stephen; the CD1013 Study Investigators, for

doi:10.1002/art.39962

Public

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Published in Arthritis & Rheumatology • Nov 7, 2016

Authors:

Richard Furie

Munther A. Khamashta

Joan T. Merrill

Abstract

OBJECTIVE: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE). METHODS: Patients (n = 305) were randomized to receive ...

Subject

Medicine

Clinical endpoint

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!